ReviewHuman vaccines & immunotherapeutics2016
Bispecific antibodies in cancer immunotherapy.
Review in Human vaccines & immunotherapeutics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 52 citations in OpenAlex.
- Reprogramming cancer immunity with next-generation combination therapies.Frontiers in cell and developmental biology · 2025Review
- A Comprehensive Review of the Mechanisms and Clinical Development of Monoclonal Antibodies in Cancer Therapy.Advances in experimental medicine and biology · 2025Review
- Cancer Antibody Engineering: Comparison of Mammalian, Yeast, Bacterial, Plants, Cell-free and Hybridoma Expression Systems.Current pharmaceutical biotechnology · 2025Review
- Balancing the Affinity and Tumor Cell Binding of a Two-in-One Antibody Simultaneously Targeting EGFR and PD-L1.Antibodies (Basel, Switzerland) · 2024Article
- 10 years of BiTE immunotherapy: an overview with a focus on pancreatic cancer.Frontiers in oncology · 2024Review
- Characteristics and treatment results of refractory and relapsed acute myeloid leukaemia in paediatric patients treated in Polish Paediatric Leukaemia/Lymphoma Study Group institutions according to the Protocol Acute Myeloid Leukaemia Berlin-Frankfurt-Munster 2012 and a review of novel treatment possibilities in paediatric acute myeloid leukaemia.Contemporary oncology (Poznan, Poland) · 2023Article
- Emerging Trends in Immunotherapy for Cancer.Diseases (Basel, Switzerland) · 2022Review
- Review
- Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation and Increase Anti-Tumor Efficacy.International journal of molecular sciences · 2022Article
- Clinical safety and efficacy of bispecific antibody in the treatment of solid tumors: A protocol for a systematic review.PloS one · 2022Article
- A Generic Strategy to Generate Bifunctional Two-in-One Antibodies by Chicken Immunization.Frontiers in immunology · 2022Article
- Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications.Molecular therapy oncolytics · 2021Review
- Review
- Etiologic Role of Kinases in the Progression of Human Cancers and Its Targeting Strategies.Indian journal of surgical oncology · 2021Article
- A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.Frontiers in immunology · 2021Article
- Harnessing and Enhancing Macrophage Phagocytosis for Cancer Therapy.Frontiers in immunology · 2021Review
- The recombinant anti-TNF-α fusion protein ameliorates rheumatoid arthritis by the protective role of autophagy.Bioscience reports · 2020Article
- Photocontrolled activation of small molecule cancer therapeutics.RSC medicinal chemistry · 2020Review
- Article
- Bispecific antibodies: Potential immunotherapies for HIV treatment.Methods (San Diego, Calif.) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied. Among the various approaches to cancer immunotherapy, 2 bispecific antibodies are currently approved for patient care. Many more bispecific antibodies are now in various phases of clinical development and will become the next generation of antibody-based therapies. Further understanding of immunology and advances in protein engineering will help to generate a greater variety of bispecific antibodies to fight cancer. Here, we focus on bispecific antibodies that recruit immune cells to engage and kill tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.